Aquestive Therapeutics (AQST) stock

Market cap $587M

$4.59

-3.47%

Prices 18 minutes old, as of 10:07 AM ET. Members see real-⁠time prices.

Quality Score

-1

Poor

In its industry

#163of 260

Biotech

Checks firing

2of 14

Transition

From 52-week high

-39.3%

Above the 200-day

Cash$98.5M, about 8 quarters (2 years) at the last year's spendingOn Jun 30 · the company says “into 2027”

Follow AQST's news. Members get an alert when Aquestive Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when AQST files news8 days free. No card.

Cash$98.5M, about 8 quarters (2 years) at the last year's spendingOn Jun 30 · the company says “into 2027”

Pipeline and cash

What's next for AQST, and how long its cash lasts

From Aquestive Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words and the arithmetic, not a forecast. Companies often miss their own dates.

Cash runway to Jun 30

About 8 quarters

$98.5M in cash ÷ $11.3M used a quarter over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's own estimate, which counts its plans, is “into 2027” (8-K, May 13).

For members: the share count, 4 raises, 2 shelf filings, and the math.

Daniel BarberPresident and CEOFrom their own Form 4 filings

For members: their 25 filings and quotes, and an alert each time they file.

Get an alert when AQST files news8 days free. No card.

Biotech dates

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first.

MRKMerck · $367BOct 4FDA date11
IONSIonis Pharmaceuticals · $7.4BOct 26FDA date-3
INOInovio Pharmaceuticals · $122MOct 30FDA date-7

59 more companies with an FDA date or a trial due in these 60 days. Members see every one, with its score and cash runway, sorted by date.Get in free →

Quality Score

Why AQST scores -1

PoorTransition, 2 of 14 checks firingWhat the Quality Score means

Poor is below 0. Average starts at 6, Above Average at 11, Excellent at 15, and Exceptional at 20.

+2Momentum traits 2 of 14 firing right now, one point each
+2Growth sales up 23% on the year, gross margin up 5.9 pointsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.

Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Long-term trend, Run-up, Size, Persistence, and News.

What every line is worth, and the reason behind it, on AQST and every other stock.Get in free →

Price, score, traits, and the industry rank are from a snapshot taken at 10:07 AM ET, at least 15 minutes behind. How we rank stocks.

What's next

Expected to report Wed Nov 4, after the close

After its last 4 reports it closed +2.5% on average, higher 2 of 4 times.

What would turn AQST's score around: 9 things, for members

Alert me when AQST's Quality Score turns up

8 days free. No card. No account needed today.

For members

Here is what members see.

Every stock gets a card like this one, and a page with its price in real time, every line of its score, the chart, and its filings.

A member's scanner card for AMD: the Quality Score badge, the rank in the scan and in its industry, the momentum bar, three plain lines on its strength, notable holders, and early signs, and pills for size, volume, RSI, and short interest — A card on the scanner, shown on AMD

A member's stock page for AMD: the price, the Quality Score, the rank, the traits firing, relative strength, and the chart — A stock page

The scanner a member sees: every stock as a card with its Quality Score, rank, and momentum bar, the watchlist, and the day's top gainers — The scanner

The 14 checks

AQST has 2 of 14 checks firing

One per group is shown here.

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Averages stacked in order, price near its high.

Volume1 of 3 shown

VOL VDU U/D VOL

Heavy volume on the run, quiet volume at rest.

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

The daily range is tight against its own recent history.

Buying1 of 3 shown

OBV+CLOSE HI SPRING

Closes near the high, and buyers step in on dips.

The other 10 checks on AQST, and all 14 on every stock.Get in free →

Its industry

How AQST ranks in Biotech

AQST is #163 of 260 by Quality Score. The top three are shown with their scores, and the rest by name.

1PBYIPuma Biotechnology10/1419
2ABCLAbCellera Biologics9/1419
3RGENRepligen7/1419
AMRXAmneal PharmaceuticalsOpen for its score
EXELExelixisOpen for its score
163AQSTAquestive Therapeutics2/14-1

More in Biotech, on the Healthcare page →

Earnings

When does AQST report, and what happens after?

Expected to report Wed Nov 4, after the close (in 36 days). Not yet confirmed by the company.

+2.2%-2.5%+14.5%-4.1%

Nov 5Mar 4May 13Aug 11

Reported	When	Gap	Reaction	5 sessions
Aug 11, 2026After close	After close	-3.2%	-4.1%	-2.0%
May 13, 2026After close	After close	+15.0%	+14.5%	+1.0%
Mar 4, 2026After close	After close	-2.5%	-2.5%	-2.3%
Nov 5, 2025After close	After close	+8.0%	+2.2%	-7.0%

The gap is the next open against the close before the report; the reaction is where that session closed. AQST closed higher after 2 of its last 4. Past behavior, not a forecast.

Report dates and past reactions come from sessions that have already closed, so none of these figures move.

The company

About Aquestive Therapeutics

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

147 employeesWarren, NJaquestive.com

For members

Every line of the score, on every stock.

Real-time prices, no delay
Every line of AQST's score, with the points and the reason
All 14 checks on AQST and on all 2,952 stocks
Every stock ranked, with the chart
Every filing, and optional alerts on AQST

See all 14 checks on AQST8 days free. No card. No account needed today.

Questions

Straight Answers.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Where does the data come from?

Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week traits rest on real history. Options flow is not part of the product.

What does it cost?

Nothing for the first 8 days. After that, one plan with everything in it, only if you choose to subscribe: $29 a month, $69 for three months, or $249 a year. Payments go through Stripe, so Breakaway never sees your card.

Is this investment advice?

No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.

The price, the score, the traits, and the industry rank on this page are delayed at least 15 minutes. Filings are shown as filed, because a disclosure is already days or weeks old when it becomes public. Earnings dates and past reactions are settled sessions.